InvestorsObserver
×
News Home

Vyne Therapeutics Inc (VYNE) Stock: Buy, Hold, or Sell?

Wednesday, January 27, 2021 11:38 AM | InvestorsObserver Analysts

Mentioned in this article

Wall Street is positive on Vyne Therapeutics Inc (VYNE). On average, analysts give VYNE a Strong Buy rating. The average price target is $6.312, which means analysts expect the stock to increase by 164.10% over the next twelve months.

That average ranking earns VYNE an Analyst Rating of 79, which is better than 79% of stocks based on data compiled by InvestorsObserver.

Overall Score - 5
Wall Street analysts are rating VYNE a Strong Buy today. Find out what this means to you and get the rest of the rankings on VYNE!

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.

InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Vyne Therapeutics Inc Stock Today?

Vyne Therapeutics Inc (VYNE) stock is trading at $2.39 as of 11:35 AM on Wednesday, Jan 27, a decline of -$0.11, or -4.4% from the previous closing price of $2.50. The stock has traded between $2.33 and $2.47 so far today. Volume today is elevated. So far 8,786,219 shares have traded compared to average volume of 6,262,340 shares.

Click Here to get the full report on Vyne Therapeutics Inc (VYNE) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App